[Editor’s note: Jim Greenwood is president and CEO of the Biotechnology Industry Organization.]
[On July 19], experts at the U.S. Food and Drug Administration (FDA) convened to hear evidence about a new kind of cancer breakthrough from Novartis that can cure children and young adults with an intractable, debilitating, life-shortening and heretofore untreatable cancer.…
Chimeric Antigen Receptor T-cell gene therapy takes a type of white blood cell called T cells and genetically alters the cells to do what fully functional immune cells should do: fight off invaders…
The CAR-T breakthrough has been shown to be effective in more than 80 percent of the ALL patients tested, many of them children. But as is often the case with miracles, there can be a catch: in this case, serious side effects that, if not properly addressed, can hasten the patient’s death…
Our hope now is that the Novartis breakthrough will be the first in a coming wave of approvals for personalized medicines customized to help patients beat disease using their own modified cells…
Today, CAR-T therapy is seen as a route to healing for young people tragically affected by a rare leukemia unresponsive to available treatments. Tomorrow, who knows? Already, there are investigations under way to determine if this method can be used to treat other kinds of cancer in different patient populations
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Green Light for CAR-T Leukemia Treatment Is an Historic Moment for Biotechnology
